Journal article · 2026 · Open access

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial

Ben George, Harshabad Singh, Craig Devoe, Vincent M. Chung, Peter J. Hosein, Andrew Hendifar, Dae Won Kim, Jennifer Brooke Valerin, Tanios Bekaii‐Saab, Dana Backlund Cardin, Manuel M. Hidalgo, Pashtoon Murtaza Kasi and 24 more

Nature Medicine · Published 23 October 2026 · DOI 10.1038/s41591-026-04734-7

Open PDFView at the publisherCite this paper

In brief

“Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial” is a 2026 journal article by Ben George and 35 co-authors, published in Nature Medicine. OpenAlex counts 1 citations as of 18 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Nature Medicine.

Citations
1
Most cited in
2026 (1)
Field-weighted impact
2.15
References
48
Authors
36

Abstract

Camupepimut (ELI-002 7P) drives mutated KRAS (mKRAS)-specific T cell responses that correlated with disease-free survival (DFS) and overall survival (OS) in patients with mKRAS pancreatic adenocarcinoma (PDAC) in the phase 1 AMPLIFY-201 trial. In the phase 2 AMPLIFY-7P trial, patients with stage I-III KRAS-mutated PDAC without recurrence within 6 months of standard therapy were randomized 2:1 to camupepimut (n = 96) or standard-of-care/observation (n = 48). Stratification balanced nodal status. The primary DFS endpoint was not met (median 23.8 versus 21.2 months; HR 0.85, P = 0.5329). However, prespecified and exploratory analyses were informative. A numerical DFS advantage at 6 months of 14.0% (75.7% versus 61.7%; HR 0.55, P = 0.0557) corresponded to camupepimut dosing. Post hoc multivariate Cox regression analysis of DFS indicated an improved outcome for camupepimut (adjusted HR 0.47, P = 0.0086), a worse outcome for stage III disease (adjusted HR 2.29, P = 0.0127), an elevated baseline CA19-9 (adjusted HR 3.16, P < 0.0001) and baseline circulating tumor DNA (ctDNA) positivity (adjusted HR 5.99, P < 0.0001). Prespecified subgroup analyses addressing prognostic and predictive factors suggested DFS benefit for camupepimut (ctDNA negative: HR 0.51, P = 0.0280; no prior radiation: HR 0.59, P = 0.0221). Exploratory analysis demonstrated that ex vivo mKRAS-specific T cell responses were robust (98.9%, 89/90) and associated with antigen spreading (86.7%, 13/15). In camupepimut-treated patients, mKRAS-specific T cell response >9.17-fold over baseline (82.2%, 74/90) correlated with improved DFS (HR 0.22, P < 0.0001), with the median DFS not reached versus 6.08 months for above and below 9.17-fold, respectively. Camupepimut safety was similar to observation, with grade ≥3 adverse events in 10.4% (10/96) versus 14.6% (7/48), and few serious AEs (6.3%, 6/96 versus 8.3%, 4/48; reflecting progression/surgical complication). These efficacy and immunogenicity signals will inform a refined strategy for a confirmatory phase 3 trial. ClinicalTrials.gov identifier: NCT05726864 .

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

George, B., Singh, H., Devoe, C., Chung, V. M., Hosein, P. J., Hendifar, A., Kim, D. W., Valerin, J. B., Bekaii‐Saab, T., Cardin, D. B., Hidalgo, M. M., Kasi, P. M., Leal, A. D., Pelster, M. S., Fei, N. H., Weekes, C. D., O’Hara, M. H., George, T. J., Kazmi, S. M. A., . . . O'Reilly, E. M. (2026). Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial. Nature Medicine. https://doi.org/10.1038/s41591-026-04734-7

MLA 9

George, Ben, et al. “Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial.” Nature Medicine, 2026. https://doi.org/10.1038/s41591-026-04734-7.

Chicago

George, Ben, Harshabad Singh, Craig Devoe, Vincent M. Chung, Peter J. Hosein, Andrew Hendifar, Dae Won Kim, et al. 2026. “Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial.” Nature Medicine. https://doi.org/10.1038/s41591-026-04734-7.

Harvard

George, B. et al. (2026) ‘Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial’, Nature Medicine. doi:10.1038/s41591-026-04734-7.

IEEE

B. George et al., “Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial,” Nature Medicine, 2026, doi: 10.1038/s41591-026-04734-7.

BibTeX

@article{george2026lymph,
  title     = {{Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial}},
  author    = {George, Ben and Singh, Harshabad and Devoe, Craig and Chung, Vincent M. and Hosein, Peter J. and Hendifar, Andrew and Kim, Dae Won and Valerin, Jennifer Brooke and Bekaii‐Saab, Tanios and Cardin, Dana Backlund and Hidalgo, Manuel M. and Kasi, Pashtoon Murtaza and Leal, Alexis Diane and Pelster, Meredith S. and Fei, Naomi H. and Weekes, Colin D. and O’Hara, Mark H. and George, Thomas J. and Kazmi, Syed Mohammad Ali and Mizrahi, Jonathan D. and Nair, Suresh and Maiers, Martin J. and Kheoh, Thian San and Amato, Gianni and Xavier, Jino and Snyder, Julia Priscilla and Milaszewski, Madison H. and Cabana-Puig, Xavier and Perry, James and McNeil, Lisa Kristin and others},
  journal   = {Nature Medicine},
  year      = {2026},
  doi       = {10.1038/s41591-026-04734-7},
  url       = {https://doi.org/10.1038/s41591-026-04734-7}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research

  • disease-free survival
  • circulating tumor DNA
  • CA19-9
  • prognostic and predictive biomarkers
  • antigen spreading

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

George, B., Singh, H., Devoe, C., Chung, V. M., Hosein, P. J., Hendifar, A., Kim, D. W., Valerin, J. B., Bekaii‐Saab, T., Cardin, D. B., Hidalgo, M. M., Kasi, P. M., Leal, A. D., Pelster, M. S., Fei, N. H., Weekes, C. D., O’Hara, M. H., George, T. J., Kazmi, S. M. A., . . . O'Reilly, E. M. (2026). Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial. Nature Medicine. https://doi.org/10.1038/s41591-026-04734-7

How many times has this paper been cited?

1 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Nature Medicine: sign in and open the PDF from this page.

Who wrote this paper?

Ben George, Harshabad Singh, Craig Devoe, Vincent M. Chung, Peter J. Hosein, Andrew Hendifar, Dae Won Kim, Jennifer Brooke Valerin, Tanios Bekaii‐Saab, Dana Backlund Cardin, Manuel M. Hidalgo, Pashtoon Murtaza Kasi and 24 more.

What is the DOI of this paper?

10.1038/s41591-026-04734-7, permanently at https://doi.org/10.1038/s41591-026-04734-7. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.